Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.84)
# 693
Out of 5,090 analysts
42
Total ratings
57.14%
Success rate
9.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $4.37 | +83.28% | 2 | Nov 24, 2025 | |
| IMNM Immunome | Maintains: Overweight | $25 → $33 | $20.12 | +64.02% | 3 | Nov 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $12.62 | +18.91% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $10.09 | +78.39% | 4 | Nov 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Overweight | $15 | $5.29 | +183.82% | 1 | Oct 28, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $29.48 | +18.74% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.60 | +130.77% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $35.95 | +25.17% | 3 | Sep 9, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $18.00 | +66.67% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $44.40 | +35.15% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $23.14 | +42.64% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.54 | +125.99% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $7.19 | +108.62% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $60 | $66.56 | -9.86% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.45 | +244.83% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $10.00 | +900.00% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.04 | +882.80% | 1 | May 14, 2024 |
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.37
Upside: +83.28%
Immunome
Nov 17, 2025
Maintains: Overweight
Price Target: $25 → $33
Current: $20.12
Upside: +64.02%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $12.62
Upside: +18.91%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $10.09
Upside: +78.39%
Candel Therapeutics
Oct 28, 2025
Initiates: Overweight
Price Target: $15
Current: $5.29
Upside: +183.82%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $29.48
Upside: +18.74%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.60
Upside: +130.77%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $35.95
Upside: +25.17%
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $18.00
Upside: +66.67%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $44.40
Upside: +35.15%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $23.14
Upside: +42.64%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.54
Upside: +125.99%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.19
Upside: +108.62%
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $66.56
Upside: -9.86%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.45
Upside: +244.83%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $10.00
Upside: +900.00%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.04
Upside: +882.80%